(640d) Polymer Lung Surfactant: A First-in-Class Synthetic Surfactant Therapeutic for Acute Respiratory Distress Syndrome (ARDS)

Acute Respiratory Distress Syndrome (ARDS) is a life-threatening condition affecting about 200,000 patients in the United States each year. When ARDS occurs, the function of native lung surfactant becomes impaired, contributing to a severe decrease in blood oxygenation and eventually multiple organ failures. There are currently no therapeutic surfactant formulations which have been shown to be effective in treating this condition; all prior clinical trials testing animal-derived lung surfactants in ARDS patients were unsuccessful. Our laboratory has been exploring a radically different approach, in which, instead of conventional lipid/protein-based formulations, synthetic biocompatible polymers are used as the active therapeutic ingredient. This investigation led to the development of a treatment which uses an amphiphilic block copolymer formulation. This formulation has been shown to be more effective in ARDS mouse models compared to clinically available animal derived surfactants. The polymer formulation is a promising candidate for lung surfactant replacement therapy as it forms an insoluble monolayer at the alveolar air-water interface which is resistant to serum protein/phospholipase deactivation. This talk will present accounts of our research endeavors over the past few years that enabled the development of this first-in-class polymer lung surfactant therapy for ARDS treatment.